Miraculins Announces Publication of Peer-Reviewed Study That Demonstrates Scout DS(R) Is a Viable Alternative to Current Pre-...

Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical
diagnostic company focused on acquiring, developing and commercializing
diagnostic tests and risk assessment technologies for unmet clinical needs,
today announces the publication of results from the ENGINE (Evaluation of a
Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes) study,
which highlights the effectiveness of the Company's Scout DS(R) NonInvasive
Diabetes Screening Device. The study, which is available online ahead of press
publication by the Journal of Clinical and Translational Endocrinology,
concluded that the elimination of overnight fasting, the absence of blood, and
the rapid, real-time communication of screening results are aspects of
noninvasive skin fluorescence spectroscopy (Scout DS(R) measurement) that
facilitate opportunistic screening of individuals at risk for type 2 diabetes,
while delivering performance that is comparable to fasting plasma glucose and
HbA1c testing for detection of abnormal glucose tolerance. The published article
is entitled "Noninvasive Skin Fluorescence Spectroscopy for Detection of
Abnormal Glucose Tolerance".


"While the need for effective primary screening methods for those at risk of
developing type 2 diabetes is widely acknowledged, multiple obstacles limit the
effectiveness of established blood-based diabetes screening methods," commented
John Maynard, Vice-President Scout DS(R) Technology at Miraculins and a
co-author of the study. "The need for a blood draw negatively impacts patient
convenience and participation, while the requirement for overnight fasting by
certain methods further reduces patient compliance. The need to properly handle
and dispose of biohazardous waste generated by blood-based screening methods
presents additional challenges in mobile screening settings such as employee
wellness clinics or community health fairs." 


The ENGINE trial was a prospective, multi-centre study conducted on more than
500 patients at 12 clinical sites in the United States. The purpose of the
ENGINE trial was a real-world comparison of Scout DS(R) to fasting plasma
glucose (FPG) and HbA1c (glycated hemoglobin) for type 2 diabetes screening,
using a 2-hour oral glucose tolerance test (OGTT) as the reference standard. FPG
and HbA1c are common laboratory-based diabetes tests. All members of the study
cohort were at risk for type 2 diabetes according to the ADA (American Diabetes
Association) guidelines and therefore members of the intended-use population for
Scout DS(R). The cohort also had a representative mixture of patient age, sex,
ethnicity, and BMI (Body Mass Index). 


"The publication of this additional peer-reviewed data continues to build upon
the mounting evidence that Scout DS(R) can be an effective tool in the war on
type 2 diabetes by offering a patient friendly screening method that could
increase the likelihood of early stage disease detection," said Christopher J.
Moreau, President and Chief Executive Officer of Miraculins. 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


Scout DS(R) is a registered trademark of Miraculins Inc. All Rights Reserved. 2014. 

FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
info@miraculins.com
www.miraculins.com

Miraculins Inc. (TSXV:MOM)
過去株価チャート
から 5 2024 まで 6 2024